Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aquinox Pharmaceuticals Inc    AQXP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
10.54(c) 10.43(c) 10.35(c) 10.83(c) 11.11(c) Last
69 998 81 909 97 507 140 682 120 194 Volume
-3.13% -1.04% -0.77% +4.64% +2.59% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -49,2 M
Net income 2017 -48,5 M
Finance 2017 108 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -59,4 M
Net income 2018 -59,0 M
Finance 2018 148 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 254 M
More Financials
Company
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.It discovers and develops targeted therapeutics for inflammation and immuno-oncology.The company's primary focus is on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular... 
Sector
Pharmaceuticals
Calendar
03/19Earnings Release
More about the company
Surperformance© ratings of Aquinox Pharmaceuticals In
Trading Rating : Investor Rating : -
More Ratings
Latest news on AQUINOX PHARMACEUTICALS IN
11/09 AQUINOX PHARMACEUTICALS : Announces Third Quarter 2017 Financial Results
11/08 AQUINOX PHARMACEUTICALS, INC. (NASDA : AQXP) Files An 8-K Results of Operations ..
11/08 AQUINOX PHARMACEUTICALS : reports 3Q loss
11/08 AQUINOX PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/08 AQUINOX PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Fi..
11/08 Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
09/18 AQUINOX PHARMACEUTICALS : to Present at 2017 Cantor Fitzgerald Global Healthcare..
08/29 AQUINOX PHARMACEUTICALS : Statement on FDA Advisory Committee Meeting to Discuss..
08/28 Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial C..
08/08 AQUINOX PHARMACEUTICALS : reports 2Q loss
More news
Sector news : Pharmaceuticals - NEC
07:42aDJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
07:31aDJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/16 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
11/15 BAYER : Monsanto, U.S. farm groups sue California over glyphosate warnings
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/08 Aquinox Pharma beats by $0.09
09/05 ROTY VOLUME 1 EDITION 27 : Spring Bank And Anaptysbio Making Moves Higher + A Ne..
09/01 AQUINOX PHARMACEUTICALS : Buy, Sell Or Hold?
08/31 ROTY VOLUME 1 EDITION 25 : Swapping Out Weakness For Strength
08/17 ROTY EDITION 1 VOLUME 22 : Insider Buys, Updates And Trades
Chart AQUINOX PHARMACEUTICALS IN
Duration : Period :
Aquinox Pharmaceuticals In Technical Analysis Chart | AQXP | US03842B1017 | 4-Traders
Technical analysis trends AQUINOX PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 25,0 $
Spread / Average Target 131%
EPS Revisions
Managers
NameTitle
David J. Main Chairman, President & Chief Executive Officer
Kamran Alam Chief Financial Officer, Secretary & VP
David Green Vice President-Global Clinical Operations
Barbara Troupin Chief Medical Officer & VP-Clinical Development
Daniel J. Levitt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AQUINOX PHARMACEUTICALS INC-37.31%254
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
ROCHE HOLDING LTD.-2.06%200 423
MERCK AND COMPANY-6.91%150 468